NEW YORK, June 24 (Reuters) - Cigna CI.N sued Bristol Myers BMY.N on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over a blockbuster multiple myeloma drug sold under the brand name Pomalyst.
The insurer said Bristol Myers and its Celgene unit have delayed generic versions of Pomalyst from entering the market, causing Cigna and other purchasers to overpay by hundreds of millions, and perhaps billions, of dollars.
Cigna filed its lawsuit in Manhattan federal court.
(Reporting by Jonathan Stempel in New York)
((jon.stempel@thomsonreuters.com; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.